# A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Study · id `cardio:ct-nct03922750` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03922750](<https://clinicaltrials.gov/study/NCT03922750>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03922750

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

## Technical summary

Registry record NCT03922750. Randomized; no masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2019-12-19 (actual). Results posted on 2021-01-08.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 154 participants (enrolled count; ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Started: 2019-05-09 (actual) (ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Primary completion: 2019-12-19 (actual) (ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Completion: 2020-01-27 (actual) (ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Results first posted: 2021-01-08 (ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Countries: United States; Canada; Czechia; Germany; Italy (ClinicalTrials.gov record NCT03922750, source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03922750-2022-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin icodec
- Intervention (Drug): Insulin glargine U100
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial (`cardio:pubmed-33875485`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f553657bb032570e706c2f9cfdfa07f354536b5c474eb7483b57c39786103121
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
